Abstract:Amyotrophic lateral sclerosis (ALS) is a rare neuromuscular disease with a wide disease progression. Despite several efforts to develop efficient biomarkers, many concerns about the available ones still need to be addressed. MicroRNA (miR) are non-coding RNAs that can modulate molecular circuits and are involved in ALS pathogenic mechanisms. 22 fast and 23 slow-progressing-defined ALS patients were recruited. ALSFRS-R, strength, respiratory function, nerve conduction studies, and creatine kinase were evaluated at the baseline and after 6 months of follow-up. The mean monthly reduction of the previous variables (progression index – PI) was calculated. MiR206, 133a-3p, 151a-5p, 199a-5p, and 423-3p were dosed. The univariate analysis showed an independent reduction of miR206 and an increase of miR423-3p in patients with a slow slope of ALSFRS-R and weakness, respectively. MiR206 and 423-3p are differently modulated in fast and slow-progressing ALS patients, suggesting a role for microRNAs in prognosis and therapeutic target.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is whether patients with different progression rates in Amyotrophic Lateral Sclerosis (ALS) can be distinguished by specific microRNA (miRNA) levels. Specifically, the researchers focused on the expression differences of miR206 and miR423 - 3p in ALS patients with rapid and slow progression, and whether these differences can be used as prognostic markers or treatment targets. ### Research Background ALS is a rare neuromuscular disease characterized by the progressive degeneration of upper and lower motor neurons, usually leading to death within 3 years after diagnosis. Despite extensive efforts, there is still a lack of effective biomarkers to predict the disease progression rate at present. MicroRNA (miRNA) is a class of non - coding RNAs that can regulate molecular circuits and are involved in the pathogenic mechanism of ALS. Therefore, studying the expression differences of miRNA in ALS patients with different progression rates may help to discover new prognostic markers or treatment targets. ### Research Methods - **Sample Selection**: The study included 45 diagnosed ALS patients, of which 22 were of the rapid - progression type and 23 were of the slow - progression type. Patients were divided into two groups according to the ALSFRS - R score slope (progression index) after 6 months. The slope of the rapid - progression type was greater than 0.5 points/month, and the slope of the slow - progression type was less than 0.5 points/month. - **Clinical Evaluation**: At baseline and 6 - month follow - up, the ALSFRS - R score, MRC score, FVC, cMAP amplitude and serum creatine kinase (CK) of the patients were evaluated. - **miRNA Detection**: Circulating miRNA was extracted from 200 µL serum, and the expression levels of miR206, miR133a - 3p, miR151a - 5p, miR199a - 5p and miR423 - 3p were detected using real - time quantitative PCR (qRT - PCR). ### Main Results - **Expression of miR206**: The expression of miR206 in rapid - progression patients was significantly higher than that in slow - progression patients. The expression level of miR206 can better distinguish between rapid - and slow - progression patients, with an optimal cut - off value of 0.245, a sensitivity of 63.6% and a specificity of 73.9%. - **Expression of miR423 - 3p**: The expression of miR423 - 3p was negatively correlated with the progression slope of the MRC score, that is, patients with higher miR423 - 3p levels had a slower decline in the MRC score and a better prognosis. - **Regression Analysis**: Univariate and multivariate analyses showed that the expression levels of miR206 and miR423 - 3p were related to the progression slopes of patients' clinical indicators (such as ALSFRS - R score, MRC score, FVC, etc.). ### Conclusions This study shows that there are significant differences in the expressions of miR206 and miR423 - 3p in ALS patients with rapid and slow progression. These miRNAs may serve as prognostic markers and help predict the disease progression rate of patients. In addition, the expression differences of these miRNAs may also reveal the pathological mechanism of ALS and provide potential targets for future treatment. ### Possible Applications - **Prognostic Markers**: By detecting the expression levels of miR206 and miR423 - 3p, doctors can be helped to more accurately predict the disease progression rate of patients, so as to develop more personalized treatment plans. - **Treatment Targets**: Understanding the mechanism of action of these miRNAs in ALS may provide clues for the development of new treatment methods. In general, this study provides a new perspective for the early diagnosis and prognostic evaluation of ALS, which is helpful to improve the management and treatment effect of patients.

MiR206 and 423-3p Are Differently Modulated in Fast and Slow-Progressing Amyotrophic Lateral Sclerosis Patients

Potential therapeutic targets for ALS: MIR206, MIR208b and MIR499 are modulated during disease progression in the skeletal muscle of patients

Exploiting the role of CSF NfL, CHIT1, and miR-181b as potential diagnostic and prognostic biomarkers for ALS

Expression Changes of miRNAs in Humans and Animal Models of Amyotrophic Lateral Sclerosis and Their Potential Application for Clinical Diagnosis

An integrative miRNA-mRNA expression analysis identifies miRNA signatures associated with SOD1 and TARDBP patient-derived motor neurons

Systematic review and meta-analysis of dysregulated microRNAs derived from liquid biopsies as biomarkers for amyotrophic lateral sclerosis

A microRNA diagnostic biomarker for amyotrophic lateral sclerosis

Cerebrospinal Fluid Neurofilament Light Chain (NfL) Predicts Disease Aggressiveness in Amyotrophic Lateral Sclerosis: An Application of the D50 Disease Progression Model

Differentially expressed lncRNAs in SOD1G93A mice skeletal muscle: H19, Myhas and Neat1 as potential biomarkers in amyotrophic lateral sclerosis

Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients

Sporadic Amyotrophic Lateral Sclerosis Skeletal Muscle Transcriptome Analysis: A Comprehensive Examination of Differentially Expressed Genes

MicroRNA expression in animal models of amyotrophic lateral sclerosis and potential therapeutic approaches

Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis

Inflammatory signature in amyotrophic lateral sclerosis predicting disease progression

Expression of microRNA-29 b in mice with amyotrophic lateral sclerosis

An RNA-seq study in Friedreich ataxia patients identified hsa-miR-148a-3p as a putative prognostic biomarker of the disease

A Panel of miRNA Biomarkers Common to Serum and Brain-Derived Extracellular Vesicles Identified in Mouse Model of Amyotrophic Lateral Sclerosis

Micro-RNAs Shuttled by Extracellular Vesicles Secreted from Mesenchymal Stem Cells Dampen Astrocyte Pathological Activation and Support Neuroprotection in In-Vitro Models of ALS

Amyotrophic lateral sclerosis stratification: unveiling patterns with virome, inflammation, and metabolism molecules

Stratifying Disease Stages with Different Progression Rates Determined by Electrophysiological Tests in Patients with Amyotrophic Lateral Sclerosis.

Association of MicroRNA Expression and Serum Neurofilament Light Chain Levels with Clinical and Radiological Findings in Multiple Sclerosis